Tag: Cylerus
Local drug delivery to prosthetic vascular grafts: Preventing failure of prosthetic grafts in haemodialysis patients
Dr Ronald J. Shebuski, President and CEO of Cylerus, Inc., wants to revolutionise the way vascular grafts work. His company, Cylerus, has an innovative way to deliver an antiproliferative drug, sirolimus, in a consistent and controlled manner. This method of drug delivery, via a porous graft material called ePTFE, has the potential to reduce failure of arterio-venous access grafts crucial for […]